Thor Medical ASA (LTS:0R6Y) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Days Payable?

Thor Medical ASA's average Accounts Payable for the three months ended in Dec. 2023 was kr2.75 Mil. Thor Medical ASA's Cost of Goods Sold for the three months ended in Dec. 2023 was kr0.00 Mil.

The historical rank and industry rank for Thor Medical ASA's Days Payable or its related term are showing as below:

LTS:0R6Y's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Thor Medical ASA's Days Payable stayed the same from Mar. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Thor Medical ASA Days Payable Historical Data

The historical data trend for Thor Medical ASA's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Days Payable Chart

Thor Medical ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Thor Medical ASA Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Thor Medical ASA's Days Payable

For the Biotechnology subindustry, Thor Medical ASA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thor Medical ASA's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's Days Payable distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's Days Payable falls into.

Thor Medical ASA Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Thor Medical ASA's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (9.093	+	2.103)	/	2 )	/	0	*	365
=	5.598					/	0	*	365
=	N/A

Thor Medical ASA's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (3.4	+	2.103)	/	2 )	/	0	*	365 / 4
=	2.7515					/	0	*	365 / 4
=	N/A

Thor Medical ASA Days Payable Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Thor Medical ASA (LTS:0R6Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

TRMED:Norway 8NN:Germany

Address

Kjelsasveien 168 B, Oslo, NOR, 0884

Website

https://www.nordicnanovector.com

Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin.

Thor Medical ASA (LTS:0R6Y) Headlines

No Headlines